Cyclerion Therapeutics, Inc.
CYCNNASDAQHealthcare● Active
$3.01
+$0.03(+1.01%)
Market Cap$13034233
P/E Ratio—
52W High$8.48
52W Low$1.027
Cyclerion Therapeutics, Inc. (CYCN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CYCN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.76
Est. -$17.20 · +95.6%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS🔥 5-Quarter EPS Beat Streak
CYCN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$7.10 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 15, 2026 | — | — | — | — | — | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$17.20 | -$0.76 | +95.6% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.38 | -$0.19 | +50.0% | $0.00B | $0.00B | +0.0% |
| — Q1 FY2026 | Mar 25, 2026 | -$0.38 | -$0.38 | +0.0% | $0.00B | $0.00B | +0.0% |
| — Q4 FY2025 | Nov 12, 2025 | — | -$0.30 | — | $0.00B | — | — |
| — Q3 FY2025 | Aug 5, 2025 | — | -$0.11 | — | $0.00B | — | — |
| — Q2 FY2025 | May 6, 2025 | — | -$0.56 | — | $0.00B | — | — |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$7.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.76
EPS Est.
-$17.20
EPS Surpr.
+95.6%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.38
EPS Surpr.
+50.0%
Revenue
$0.00B
Q1 FY2026
Mar 25, 2026
EPS Actual
-$0.38
EPS Est.
-$0.38
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025
EPS Actual
-$0.30
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Aug 5, 2025
EPS Actual
-$0.11
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 6, 2025
EPS Actual
-$0.56
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $-7.40 | $-7.40 | $-7.40 | 1 |
| Q2 FY2029 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q1 FY2029 | $-5.60 | $-5.60 | $-5.60 | 1 |
| Q4 FY2028 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q3 FY2028 | $-7.40 | $-7.40 | $-7.40 | 1 |
| Q2 FY2028 | $-6.40 | $-6.40 | $-6.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +95.6% | $3.19 | $3.18 | -0.31% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +50.0% | $1.51 | $1.45 | -3.97% |
| ▲ Q1 FY2026 | Mar 25, 2026 | +0.0% | $1.64 | $1.62 | -1.22% |
| — Q4 FY2025 | Nov 12, 2025 | — | $1.61 | $1.42 | -11.80% |
| — Q3 FY2025 | Aug 5, 2025 | — | $2.79 | $2.89 | +3.58% |
| — Q2 FY2025 | May 6, 2025 | — | $2.97 | $3.01 | +1.35% |
| — Q1 FY2025 | Mar 4, 2025 | — | $2.40 | $2.63 | +9.58% |
| — Q4 FY2024 | Nov 14, 2024 | — | $1.80 | $1.77 | -1.67% |
Q2 FY2026-0.31%
Report Date
May 12, 2026
EPS Beat/Miss
+95.6%
Price Before
$3.19
Price After
$3.18
Q1 FY2026-3.97%
Report Date
Mar 30, 2026
EPS Beat/Miss
+50.0%
Price Before
$1.51
Price After
$1.45
Q1 FY2026-1.22%
Report Date
Mar 25, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.64
Price After
$1.62
Q4 FY2025-11.80%
Report Date
Nov 12, 2025
EPS Beat/Miss
—
Price Before
$1.61
Price After
$1.42
Q3 FY2025+3.58%
Report Date
Aug 5, 2025
EPS Beat/Miss
—
Price Before
$2.79
Price After
$2.89
Q2 FY2025+1.35%
Report Date
May 6, 2025
EPS Beat/Miss
—
Price Before
$2.97
Price After
$3.01
Q1 FY2025+9.58%
Report Date
Mar 4, 2025
EPS Beat/Miss
—
Price Before
$2.40
Price After
$2.63
Q4 FY2024-1.67%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$1.80
Price After
$1.77
Avg Beat Reaction-1.83%
Beat Rate3 / 8 quarters
Largest Move-11.80% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CYCN ends December
Cyclerion Therapeutics, Inc. (CYCN) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.76 — beating the analyst consensus of $-17.20 by +95.6%. CYCN has beaten EPS estimates for 5 consecutive quarters. The next CYCN earnings date is expected around September 1, 2026.
Each quarter, investors track CYCN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CYCN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CYCN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CYCN earnings · 5 questionsCyclerion Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CYCN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CYCN historically reports after market close (AMC).
CYCN earnings datewhen is CYCN earningsCYCN next earnings datewhen does CYCN report earningsCYCN earnings calendar
▸ Source: FMP · Cyclerion Therapeutics, Inc. SEC filings · US GAAP · Cyclerion Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026